Applied Cells will showcase cutting-edge MARS® Bar technology at the 65th ASH Annual Meeting and Exposition
We are thrilled to be attending the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, from December 9-12. Our team looks forward to the event’s comprehensive program of signature lectures, insightful scientific workshops and dedicated special interest sessions, as well as discussing the latest developments in the field of […]
Improving cell isolation for advanced Stem Cell therapy development
Redefining CD138+ Plasma Cell Isolation for Multiple Myeloma Clinical Research
“Manufacturing Chemist” Features Our CEO, Dr. Yuchen Zhou, on Pioneering Stem Cell Separation
In a recent article published by ‘Manufacturing Chemist‘, our CEO, Dr. Yuchen Zhou, provides a comprehensive insight into the obstacles impacting stem cell therapy research. A significant issue lies in the cell separation stage, often leading to lengthy preparation times and substantial cell loss. Dr. Zhou articulates the ambition of Applied Cells Inc.: to address […]
Applied Cells Opens the CellQuest Grant to Advance Multiple Myeloma Research
We’re delighted to share the launch of the CellQuest Grant for clinical research scientists specializing in multiple myeloma and cell therapy development. This initiative, open until mid-November 2023, grants the winning researcher access to the MARS® Bar cell separation system for six months. Additionally, the package comes complete with essential reagents, training, and expert assistance. […]
CD34+ Cell Isolation from Cord Blood MNC
CD34+ cells offer valuable insights into hematopoiesis, hematological disorders, and regenerative medicine. They have potential in cancer therapies, autoimmune diseases, and genetic disorders. Isolating CD34+ cells from Cord Blood Mononuclear Cells (MNC) is crucial for research in hematopoietic stem cell biology and therapeutic advancements. MARS® Platform ensures the enrichment of CD34+ cells, enhancing purity, viability, […]
CD138+ Plasma Cell Enrichment directly from Bone Marrow
CD138 expression is a crucial marker in diagnosing plasma cell tumors and Multiple Myeloma cells. Traditionally, the evaluation of plasma cells from bone marrow involves a time-consuming and labor-intensive density gradient separation method using ficoll. However, this method leads to the loss of antigens, including CD138, from the plasma cell surface, necessitating immediate staining and […]
Applied Cells Joins MassBio
We are thrilled to share the news that Applied Cells has officially become a member of MassBio! MassBio, the Massachusetts Biotechnology Council, is driven by a powerful mission: to propel Massachusetts to the forefront of life sciences leadership, fostering industry growth, enhancing the healthcare system, and ultimately improving the lives of patients. Serving as the […]
ASGCT 2023: Simple magnetic cell separation for both autologous and allogenic cell therapy development
INTRODUCTION Adoptive cell therapy has proven clinical efficacy in many cancer types and the success has driven more development of new drugs. However, on the manufacturing side, current process using conventional tools is complicated and results in suboptimal purity and yield sometimes. All those shortcomings may contribute to the high cost of the cell products […]
Simple magnetic cell separation enabled by an automated, closed system for both autologous and allogenic cell therapy development
INTRODUCTION Adoptive cell therapy has demonstrated effective clinical results in various types of cancer, leading to increased efforts in developing new drugs. However, the current manufacturing process using conventional tools is complex and often yields impure products, contributing to the high cost of cell therapy and limiting patient access. Both industry and academic cell therapy […]